Pam Kushner

May 28, 2024 | hcplive.com | Hanford Yau |Ralph A. DeFronzo |Pam Kushner |Christopher Lucci

The panel concludes by discussing the long-term outcomes for patients treated for hypercortisolism, emphasizing the need for further studies and data, and sharing their final thoughts on the disease and its future management.

May 28, 2024 | hcplive.com | Hanford Yau |Ralph A. DeFronzo |Pam Kushner |Christopher Lucci

Choosing Between Medical and Surgical Options for HypercortisolismMedical professionals discuss their ideal patients for surgery, and who would be best suited for pharmacologic intervention.

May 6, 2024 | hcplive.com | Hanford Yau |Ralph A. DeFronzo |Pam Kushner |Christopher Lucci

Patient Subgroups With a Higher Prevalence of HypercortisolismThe panel emphasizes the importance of early identification of patients based on subgroups, such as those with difficult-to-control diabetes, hypertension, and bone issues, highlighting that the inability to lower a patient's insulin dosage is a significant risk factor for hypercortisolism.

May 6, 2024 | hcplive.com | Ralph A. DeFronzo |Hanford Yau |Pam Kushner |Christopher Lucci

Christopher Lucci, MD, reviews the current diagnostic tests for hypercortisolism, which include the Dexamethasone Suppression Test, DHEA level tests, and ACTH assessments.